Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2+-advanced solid tumors, with an expansion cohort in HER2+ Metastatic Breast Cancer (MBC)

Clinical Cancer Research

Volumn 23, Issue 14, 2017, Pages 3529-3536

  Moulder, Stacy L ^a   Borges, Virginia F ^b   Baetz, Tara ^c   Mcspadden, Tessa ^b   Fernetich, Gina ^c   Murthy, Rashmi K ^a   Chavira, Renae ^e   Guthrie, Kari ^e   Barrett, Emma ^e   Chia, Stephen K ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ARRAY BIOPHARMA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; DRUG METABOLITE; LAPATINIB; TRASTUZUMAB; TUCATINIB; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; CELLULITIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; COUGHING; DIABETES INSIPIDUS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN TISSUE; HYPERCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IC90; LABORATORY TEST; LIMB PAIN; LOW DRUG DOSE; MALE; MAXIMUM TOLERATED DOSE; METASTATIC BREAST CANCER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NIGHT SWEAT; OPEN STUDY; PERIPHERAL EDEMA; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; SEPSIS; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; CLASSIFICATION; CLINICAL TRIAL; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 85024405964     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1496     Document Type: Article

References (34)

1. Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:2078-99.
2. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003;200:290-7.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
4. Figueroa-Magalhães MC, Jelovac D, Connolly RM, Wolff AC. Treatment of HER2-positive breast cancer. Breast 2014;23:128-36.
5. Li SG, Li L. Targeted therapy in HER2-positive breast cancer. Biomed Rep 2013;1:499-505.
6. HERCEPTIN® (trastuzumab) [Prescribing Information]. South San Genentech, Inc.; 2014. Available from: http://www.gene.com/download/pdf/herceptin_prescribing.pdf.
7. PERJETA® (pertuzumab) [Prescribing Information]. South San Genentech, Inc.; 2013. Available from: http://www.gene.com/download/pdf/perjeta_prescribing.pdf.
8. KADCYLA™ (ado-trastuzumab emtansine) [Prescribing Information]. South San Genentech, Inc.; 2013. Available from: http://www.gene.com/download/pdf/kadcyla_prescribing.pdf.
9. TYKERB® (lapatinib) [Prescribing Information]. Research Triangle Glax-oSmithKline; 2013. Available from: https://www.gsksource.com/gskprm/htdocs/documents/TYKERB-PI-PIL.PDF.
10. Baselga J. Treatment of HER2-overexpressing breast cancer. Ann Oncol 2010;21 Suppl 7: 36-40.
11. Wong AL, Lee SC. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int J Breast Cancer 2012;2012:415170.
12. Frankel C, Palmieri FM. Lapatinib side-effect management. Clin J Oncol Nurs 2010;14:223-33.
13. Lucchini E, Pilotto S, Spada E, Melisi D, Bria E, Tortora G. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opin Drug Saf 2014;13:535-49.
14. Sandler AB. Nondermatologic adverse events associated with anti-EGFR therapy. Oncology 2006;20:35-40.
15. Leyland-Jones B. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. J Clin Oncol 2009;27:5278-86.
16. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007;13:1648-55.
17. Pheneger T, Bouhana K, Anderson D, Garrus J, Ahrendt K, Allen S, et al. In vitro and in vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB2 [abstract]. In: Proceedings of the American Association of Cancer Research 100th Annual Meeting; 2009 Apr 18-22, 2009: AACR; 2009. Abstract nr 1795.
18. Lee P, Anderson D, Pheneger T, Napier C, Garrus J, Avrutskaya A, et al. In vivo activity of ARRY-380: A potent, small molecule inhibitor of ErbB-2 in combination with trastuzumab or docetaxel in a BT-474 human breast carcinoma xenograft model [abstract]. In: Proceedings of the American Association of Cancer Research 100th Annual Meeting; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 5581.
19. + xenograft models in mice [abstract]. In: Proceedings of the American Association of Cancer Research 103rd Annual Meeting; 2012 Mar 31-Apr 04; Chicago, IL. Philadelphia (PA): AACR; 2012. Abstract nr 852.
20. Martin V, Cappuzzo F, Mazzucchelli L, Frattini M. HER2 in solid tumors: more than 10 years under the microscope; where are we now? Future Oncol 2014;10:1469-86.
21. Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013;108:668-75.
22. Lindemann C, Fry D, Preigh M, Anderson P, Chavira R, Litwiler K, et al. Preclinical and clinical evaluation of the effect of gastric pH on exposure of ARRY-380 formulated as a crystalline freebase and a PVP-VA spray dried dispersion [abstract]. In: Proceedings of the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition; 2013 Nov 10-14; San Antonio, TX: AAPS; 2013. Abstract nr W5276.
23. + metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS); 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; 2014. Abstract nr P4-15-08.
24. + metastatic breast cancer (MBC) [abstract]. In: Proceedings of the 37th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS); 2014 Dec 9-13; San Antonio, TX.
25. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
26. Burstein HJ, Sun Y, Dirix LY, Jiang Z, Paridaens R, Tan AR, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010;28:1301-7.
27. Krop IE, Kim SB, Gonzalez-Martín A, LoRusso PM, Ferrero JM, Smitt M, et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a rando-mised, open-label, phase 3 trial. Lancet Oncol 2014;15:689-99.
28. Crown JP, Burris HA III, Boyle F, Jones S, Koehler M, Newstat BO, et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat 2008;112:317-25.
29. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-43.
30. Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2014;32:3626-33.
31. Swaby R, Blackwell K, Jiang Z, Sun Y, Dieras V, Zaman K, et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. J Clin Oncol 27:15s, 2009 (suppl; abstr 1004).
32. + Metastatic Breast Cancer (MBC) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting; 2015 Dec 8-15; San Antonio, TX: SABCS; 2015. Abstract nr P4-14-20.
33. + breast cancer central nervous system (CNS) metastases [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting; 2015 Dec 8-15; San Antonio, TX: SABCS; 2015. Abstract nr P4 -14-19.
34. Lin NU, Lee EQ, Aoyama H, Barani IJ, Barboriak DP, Baumert BG, et al. Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol 2015;16:e270-8.